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It is important to capture all health effects of interventions in cost-utility analyses conducted under a societal or 
healthcare perspective. However this is rarely done. Household spillovers (health effects on patients’ other 
household members) may be particularly likely in the context of technologies and interventions to change 
behaviours that are interdependent in the household. Our objective was to prospectively collect outcome data 
from household members and illustrate how these can be included in a cost-utility analysis of  a behaviour 
change intervention in COPD. 
Methods  
Data were collected from patients’ household members (n=153) alongside a randomised controlled trial of a 
COPD self-management intervention. The impact of the intervention on household members’ EQ-5D-5L scores 
(primary outcome), was evaluated. Analyses were then carried out to estimate household members’ QALYs and 




Results                                                        
The intervention had a negligible spillover on household members’ EQ-5D-5L scores (-0.007, p=0.75). There 
were also no statistically significant spillovers at the 5% level in household member secondary outcomes. In the 
base-case model, the inclusion of household member QALYs in the ICER denominator marginally increased the 
ICER from GBP 10,271 (EUR 13,146) to GBP 10,991 (EUR 14,068) per QALY gained. 
Conclusions 
This study demonstrates it is feasible to prospectively collect and include household members’ outcome data in 
cost utility analysis, although the study highlighted a number of methodological issues. In this case the 
intervention did not impact significantly on household members’ health or health behaviours, but inclusion of 
household spillovers may make a difference in other contexts 





Economic evaluations require consideration of the health effects of patient interventions on carers and family 
members (health spillovers), if the goal is maximising population health, rather than just patient health (1). The 
inclusion of family member quality-adjusted life years (QALYs) has been advocated for economic evaluations 
conducted under a societal perspective (2) or health care perspective (3). Under a societal perspective, all costs 
and effects of the intervention ought to be considered and typically these evaluations consider productivity 
effects of interventions. Under a healthcare perspective all health effects and healthcare costs ought to be 
considered, which in theory includes effects on, and healthcare use for, family carers and others close to the 
patient. The National Institute of Health and Care Excellence (NICE) recommends the use of the EQ-5D-5L 
instrument in cost-utility analysis for measuring the health status of patients, and the instrument may also be 
appropriate for measuring the health status of family members who are affected by health spillovers (4, 5).   
There are various mechanisms by which patient conditions can generate ‘health spillovers’. The mechanisms 
proposed to date broadly fit into three categories. The first category is the health spillover generated from 
providing informal care (i.e. additional unpaid support, such as personal care, to a family member or friend (6)) 
resulting in mental and physical strain. The second category is the mental distress experienced by family 
members from witnessing the suffering of the patient (6). The third category only relates to health spillovers 
generated by health behaviours. This mechanism concerns the imitation of patient health behaviour changes by 
surrounding individuals; with family and household members being the individuals most likely to be affected by 
this type of health spillover (7-10). It is also important to be aware of the potential for health conditions to 
strengthen the relationship with the care recipient, provide a greater determination to look after one’s own health, 
and for caregiving to make them feel useful (11-13). 
Few studies have examined the potential for health spillovers resulting from behaviour change interventions (14, 
15). A series of weight-loss trials that successfully changed dietary and physical activity behaviours in 
participants, found that the spouses of participants experienced very little change in their physical activity 
behaviour, although their diets did change as a result of adjustment in shared household food habits (15-17). 
However, a different study of an exercise trial intervention found that when participants were actively 
encouraged to recruit family members in their physical activities, there was a resultant increase in motivation in 
both participants and family members to take part in physical activity (14).  
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Looking specifically at the cost-utility analyses that have been carried out for a range of health interventions, 
there is an absence of consideration of health spillovers for behavioural interventions. Beyond behavioural 
interventions, only a handful of published trials have contemporaneously measured the spillover on family 
members’ health status and hence quality adjusted life years (QALYs) for inclusion in an economic evaluation 
(18-20). Due to this absence of trial data on spillovers, some economic evaluations have used spillover estimates 
obtained from external studies related to a different health condition; for example an economic evaluation of a 
long-acting formulation of methylphenidate for ADHD used an estimate of spillover of meningitis (21) and an 
economic evaluation of Tysabri for multiple sclerosis used an estimate of spillover of Alzheimer’s disease (22).  
An important methodological uncertainty relates to how many family/social network members should be 
included in an economic evaluation. Most economic evaluations including spillover consider one family 
member per patient (23), although we are aware of two studies which included spillover for four family 
members per patient (21, 24). More generally it has been proposed that a function could be fitted to estimate the 
multiplier effect of a health spillover through the whole family network (1). Studies do not conventionally 
include carer health care utilisation costs even when carer/household member QALYs are included (25). 
However, household members whose health improves as a result of intervention spillover may require fewer 
health care visits. Furthermore, there are controversial elements surrounding the debate on whether to include 
health spillovers in economic evaluation (26, 27).    
This study aimed to address an important need by analysing how data collection from multiple household 
members can be aligned with patient data collection in a randomised controlled trial to obtain unbiased spillover 
estimates for inclusion in a cost-utility analysis. The specific objectives of this study were two-fold. Firstly, to 
assess whether a supported self-management intervention for patients with COPD (chronic obstructive 
pulmonary disease) resulted in improved outcomes for patients’ household members. Secondly, to demonstrate 
how a within-trial economic evaluation of the COPD self-management intervention can be extended to 





We collected data at baseline and 12 months from the adult household members of patients enrolled in a 
randomised controlled trial (RCT) of a COPD self-management intervention (28). We collected data from 
household members concurrently with the data collection of patients in the RCT to estimate the effect of the 
self-management intervention on household member (and patient) outcomes. The sections that follow present, (i) 
information on the PSM-COPD (patient self-management of chronic obstructive pulmonary disease) trial (ii)  
the survey and analysis of household member outcomes ; and (iii)  the methods for including health spillovers in 
the economic evaluation of the intervention..  
 
2.1. PSM-COPD trial 
PSM-COPD was a two-arm RCT of a telephone health coaching intervention to support self-management with a 
usual care comparator group, conducted over 12 months (28). The patients enrolled in the RCT were individuals 
diagnosed with mild symptoms of their COPD (28). COPD is a progressive and irreversible respiratory disease 
which usually occurs in an older population, and encompasses conditions such as chronic bronchitis and 
emphysema (29). It is the third leading cause of death worldwide, after heart disease and strokes(30) and affects 
quality of life, with typical symptoms include frequent coughing, increasing breathlessness when active and 
frequent chest infections (31). Approximately 80% of COPD cases are attributable to cigarette smoking, and the 
most effective way to slow COPD progression is for the patient to reduce their smoking or completely stop 
smoking(31). Increased physical activity is another way for the patient to enable a slower progression of 
symptoms (31). 
A high prevalence of anxiety symptoms among COPD family members has also been noted in the quantitative 
and qualitative literature (32, 33), with 62% of mild COPD carers reporting anxiety in one study (32). COPD 
family members experience anxiety and distress particularly when patients experience exacerbations of 
breathlessness, because the occurrence of these exacerbations are unpredictable and may lead to hospitalisation 
and death of a patient(34). Better self management of COPD may therefore reduce anxiety in household 




The telephone coaching self-management intervention was comprised of four different elements which are part 
of optimal care, but are often poorly implemented in routine care (35). These elements include patients on 
smoking cessation, increasing physical activity, using the correct inhaler technique, and managing their 
medication correctly including action planning for exacerbations.  
Compared to usual care, the telephone coaching intervention was associated with non-significant improvements 
in patients' COPD health related quality of life (primary outcome), significant improvements in physical activity 
at 6 months and aspects of medication management and action planning (36). A within-trial cost-utility analysis 
of the COPD self-management intervention was carried out from a healthcare/payer perspective and included 
patient health-related QALYs as the only relevant outcome. This analysis produced an incremental cost-
effectiveness ratio for patients of GBP 10,271 (EUR 13,146) per QALY gained (incremental costs= GBP 76.44 
(EUR 97.84), incremental QALYs=0.007) (37). The main trial clinical and economic results are reported in 
more detail elsewhere (36, 37).  
 
2.2. Data collection for the family impact study (FIS) 
For the study described in this paper, we recruited household members (≥18 years) via patients enrolled in the 
RCT, between August 2014 and January 2015. Our approach was to collect data from household members at 
baseline and 12 months follow-up. At the baseline clinic assessment, patients were assessed for their eligibility 
into the main PSM-COPD trial. Once confirmed eligible, patients were provided with information about the 
family impact sub-study (FIS) and invited to participate. The patients that subsequently consented to participate 
were then provided with questionnaires according to the number of adult household members the patient lived 
with (information provided by the patients), and asked to pass on a questionnaire to each of their household 
members. Household members were requested to return the questionnaire by post within four weeks, or return a 
blank questionnaire to opt out of the study. At 12 months follow-up, questionnaires were posted directly to the 
household members, over the period August 2015-January 2016. The timing of the follow-up data collection 
was also aligned with the collection of PSM-COPD patient data at 12 months follow-up. Household members 
were excluded from the FIS if they were only temporarily residing with the person with COPD, if they returned 
a questionnaire over 4 months after it was originally sent, or if they were related to a COPD patient who 
dropped out of the trial. We did not provide a financial incentive for either patients or household members to 
participate in the FIS. 
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2.3. Household member outcomes and resource use 
We designed the baseline and follow-up household member questionnaires to measure health-related quality of 
life (using the EQ-5D-5L) and resource use spillovers. Additional items were included to assess mechanisms by 
which health and resource use spillovers were generated. In the questionnaire we collected information on 
household members’ age, sex, relationship to the patient, primary care utilisation and outcomes for health status 
(EQ-5D-5L), physical activity (IPAQ-short), stress and happiness.  
The EQ-5D-5L is a 5 item instrument used for measuring the health-related quality of life of respondents (38). 
In this study, the EQ-5D-5L was scored using the 2016 UK value set (39). Household members’ resource use 
costs relating to GP or nurse visits over the preceding 3 months were captured in the 12 month follow-up 
questionnaire. We did not anticipate important differences in household members’ secondary care visits over the 
course of the trial between intervention and control groups, so did not elicit these costs. Resource use data were 
valued by applying unit costs of GBP 45 (EUR 57) per GP visit and GBP 14.50 (EUR 19) per nurse visit, 
reported by the Personal Social Services Resource Unit (a UK social care research organisation) in 2015  (40). 
As resource use was measured over the preceding 3 months, figures were multiplied by four to estimate annual 
costs. Costs were estimated for the year 2015. Currency has been presented as both GBP and EUR. Conversions 
of GBP to EUR were performed using the exchange rate reported by the European Central Bank (ECB) on 1st 
January 2015.  
The self-management intervention was postulated to generate an improvement in the health of the COPD 
patients and increase their levels of physical activity (28). As part of the intervention, the COPD patients were 
encouraged to recruit family members and friends to participate with them in physical activities. It is also 
possible that household members might have increased their physical activity. Improvements in patients’ health 
may also result in reduced burden and stress and increased happiness in household members. It was 
hypothesised that if patients’ mean EQ-5D-5L scores increased from the telephone coaching intervention, 
household members’ mean EQ-5D-5L scores would also increase from health spillovers, albeit at a smaller 
magnitude than the patient EQ-5D-5L score improvement (8). This is because patient health improvement may 
be the result of health behaviour improvements which may stem from the patients recruiting their household 
members into physical activity participation, and also the alleviated anxiety (32), distress and care burden in 




2.4. Data analysis 
The main analysis carried out to evaluate outcomes of household members in the PSM-COPD trial were 
between-groups analyses to measure causal effects of the self-management intervention. These analyses 
compare outcomes at follow-up adjusted for baseline differences between household members in the 
intervention and usual care groups.  
Between-groups analyses were carried out using the intention-to-treat principle to assess the relative impact of 
self-management intervention compared with usual care on household member primary outcome (EQ-5D-5L 
scores) and secondary outcomes (stress, happiness, smoking and physical activity). Intention-to-treat analysis 
means that household members were analysed strictly according to the randomisation group assigned to the 
related patient at baseline (41). This methodology used to estimate treatment effect is the ‘gold standard’ 
procedure used for assessing outcomes in randomised controlled trials (42), including in assessing health 
spillover outcomes (19, 43). In the unadjusted and adjusted between-groups analyses, linear regression was used 
to regress each follow-up outcome score against the baseline outcome score and a binary variable denoting 
whether the household member was in the self-management or the usual care group. In the adjusted analyses, 
household member age and gender were also included as covariates in the linear regression, as depicted in the 
equation below as these are strong prognostic factors for the health outcomes of individuals (42).  
 
Follow-up_outcome = constant + a(baseline_outcome) + b(age) + c(gender) + d(treatment_group) + error 
We did not include treatment centre as an additional covariate for household members, as we assessed that this 
was an important prognostic factor for patient outcomes only rather than household member outcomes. For all 
regressions, we assessed whether transforming the dependent variable substantially improved the normality of 
the residuals using the ‘ladder’ command in Stata; however we did not find this to be the case for any of the 
transformations so none were implemented in the final regressions.  
Mean changes in primary and secondary outcome scores between baseline and follow-up were also presented 
for the intervention and usual care groups. The statistical significance of treatment effects in analysis was 




2.5. Economic evaluation including household members 
The methods for including household member QALYs in the within-trial cost-utility analysis of the COPD self-
management intervention are now presented. We used the multiplier approach proposed by Al Janabi et al (2016) 
which provides a theoretical framework for incorporating health spillover in economic evaluation (44). This 
approach involves adjusting patient QALYs for family spillovers generated and displaced by the intervention 
through the use of two multipliers. In the context of this study, this means accounting for household member 
QALYs in the ICER, and comparing the result to a cost-effectiveness threshold adjusted to account for 
household member QALYs lost from not funding an alternative health intervention. This approach requires us to 
be explicit about the number of individuals affected per patient, the mean spillover for these individuals and the 
spillover displaced from funding the intervention. Table 1 sets out the assumptions for each scenario. (Insert 
Table 1 here.) 
There were a very small number of patients from whom data from a second household member were collected 
(documented further in section 3.1). In these cases we only included the spouse of the patient in the analysis of 
household member costs and QALYs, as the spouse was expected to be the primary informal carer for the 
patient and also expected to form a greater concordance in health behaviour change with the patient than the 
other household member of the patient from whom data were collected (45, 46). Therefore, we characterised all 
household members included in the economic analysis as the ‘main’ household member. 
For the economic evaluation only, multiple imputation (predictive mean matching) was used to impute for 
missing EQ-5D-5L scores and costs at baseline and 12 months from the 151 main household members who 
responded to the baseline survey (there were two households where data were collected from a second 
household member; for these we only considered the patient’s spouse to be the main household member), using 
the independent variables age and gender as these were the only baseline covariates for household members 
where there were full data (47). Predictive mean matching in this study involved imputing missing EQ-5D/cost 
values by ‘borrowing’ a real value from a randomly chosen household member with complete data and similar 
age and gender characteristics. The post-imputation variables for the 151 main household members’ EQ-5D-5L 
scores at baseline and 12 months were used to calculate QALYs using the commonly used ‘area under the curve’ 
approach (or trapezium rule) (48). This approach involves multiplying the sum of EQ-5D-5L scores at baseline 
and at 12 months follow-up by 0.5 to calculate QALYs for each household member. We regressed household 
member QALYs against the treatment group variable and baseline household member EQ-5D-5L scores (48).  
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Household member incremental QALYs were adjusted through multiplying them by the proportion of 
household members that were assumed to experience a health spillover. To do this, we investigated four 
scenarios, varying assumptions regarding who experienced the spillover and whether carer health resource use 
was included. The main problem with the household member data was missingness, as 277 of the 428 
potentially eligible main household members did not participate in this study. In scenario 1 we assumed that the 
spillover for the participating household members (n=151) could be generalised to the non-participating 
household members. In scenario 2, we more conservatively assumed that only the household members who 
participated in data collection incurred spillover QALYs. In scenario 3, we used the same approach as for 
scenario 1, but additionally generalised the resource use from the 151 to the sample of household members. 
Finally, in scenario 4, we applied a spillover estimate used in scenario 1, to both the 428 main household 




To calculate the ICERs, we used as a starting point the multiplier approach to including family health spillovers 
(44), but this needed to be adapted to reflect that spillover outcomes and costs were incurred by only a 
proportion of households. To do this, we added the adjusted estimate of household member incremental QALYs 
to patient incremental QALYs in the ICER denominator (as illustrated in the equation below).   
ICER  = 
𝚫𝚫𝚫𝚫𝚫𝚫(𝐩𝐩𝚫𝐩𝐩𝐩𝚫)+   𝚫𝚫𝚫𝚫𝚫𝚫(𝐇𝐇𝚫)∗   𝐩 𝐇𝐇𝚫 𝐩𝚫𝚫𝐚𝐚𝐩𝐚 𝚫𝚫 𝐩𝐞𝐩𝐩𝐞𝐩𝐩𝐩𝚫𝐩 𝚫𝐩𝐩𝐬𝐬𝚫𝐬𝐩𝐞𝐩 𝐩𝐩𝚫𝐩𝐩𝐩𝚫𝚫 𝐩𝐩 𝚫𝐞𝐩𝐩𝐬
  𝚫𝐐𝐐𝐐𝐐𝚫(𝐩𝐩𝚫𝐩𝐩𝐩𝚫)+   𝚫𝐐𝐐𝐐𝐐𝚫(𝐇𝐇𝚫)∗    𝐩 𝐇𝐇𝚫 𝐩𝚫𝚫𝐚𝐚𝐩𝐚 𝚫𝚫 𝐩𝐞𝐩𝐩𝐞𝐩𝐩𝐩𝚫𝐩 𝚫𝐩𝐩𝐬𝐬𝚫𝐬𝐩𝐞𝐩 𝐩𝐩𝚫𝐩𝐩𝐩𝚫𝚫 𝐩𝐩 𝚫𝐞𝐩𝐩𝐬
 
 
Note 1: For scenario 3, we added adjusted household member incremental costs to patient incremental costs in 
the ICER numerator for the scenario which included household member costs as well as QALYs 
Note 2: HMs = household members 
We compared ICERs to adjusted estimates of the NICE cost-effectiveness threshold. The adjustments were 
made by dividing the NICE cost-effectiveness threshold by 1.16 for scenarios 1-3 which included one household 
member per patient, and 1.32 for scenario 4 which included two household members per patient (Table 1). 
These adjustments produced thresholds of GBP 17,241 (EUR 22,068) and GBP 15,151 (EUR 19,393) per 
QALY gained respectively. It is recommended in the methodological literature that an appropriate threshold 
deflator is required to account for the inclusion of extra QALYs in the ICER denominator (44), to represent the 
spillovers displaced through funding the intervention (as well as mitigating the inflationary effect of including 
spillovers). The deflation factors were drawn from studies which indicate that patient chronic illness on average 
generates a carer health spillover equivalent to 16% of the health loss of the patient (49, 50). These studies 
represent empirical evidence available on the ratio of carer spillover to patient health change (48), but are 
conservative in the sense that the 1.16 deflator is derived from estimates of health spillovers experienced in 
carers of chronically ill patients and does not factor in the likely lower proportional health spillover produced 





3.1. Baseline characteristics of household members  
Household members’ entry into the family impact study is summarised in supplementary Figure 1. Out of the 
448 patients available for the family impact study, 210 of the patients agreed to pass on questionnaires to 
household members, 149 patients lived alone or without another adult household member, and 89 patients did 
not consent to participate in the family impact study (FIS). From the 210 consenting households, 153 household 
members returned the survey and were included in the study at baseline (one household member per patient for 
151 patients and 2 household members per patient for two patients). 129 of these household members responded 
at follow-up. Out of the 129, 114 household members fully completed all items of the EQ-5D-5L at both 
baseline and follow-up. 
Table 2 reports baseline characteristics for household members and patients in the intervention and usual care 
groups. The average age of household members was 65.7 years, 73% of household members were female and 
93% of household members were the spouse of the patient. It can be seen at baseline that household members in 
the usual care group exhibited poorer health behaviours (smoking and exercise) than the intervention group. The 
mean EQ-5D-5L score was 0.85 for family members and 0.90 for patients. (Insert Table 2 here).  
We assessed baseline characteristics for all PSM-COPD patients, i.e. including patients whose household 
members participated in the family impact study, patients whose household members did not and patients who 
lived alone (supplementary table 1). Here, we saw that demographic and clinical characteristics were broadly 
similar across the three groups of patients, although we observed patients living alone reported worse mean EQ-
5D-5L scores, lower median physical activity and higher prevalence of smoking. Household members who were 
lost to follow-up were similar in most characteristics to those who were not (supplementary table 2), although 
they reported worse mean EQ-5D-5L scores at baseline of 0.80 relative to those who were not lost to follow-up 
(mean baseline score=0.86). 
3.2. Outcomes of household members  
The mean health status of household members in both the control group and intervention group worsened over 
the 12 months, although the declines were not significant at the 5% level (Table 3). We conducted an unadjusted 
analysis for household member outcomes where we only adjusted for the baseline outcome, as well as an 
adjusted analysis which included additional covariates of household members’ age and gender. The EQ-5D-5L 
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follow-up score (adjusted for baseline score) in both the unadjusted and adjusted analyses was slightly lower (-
0.007 in the unadjusted analysis) for household members in the intervention group, suggesting a negative effect 
of the intervention on household member health status, although this difference was not statistically significant 
(p=0.75). (Insert Table 3 here). 
Household members in the intervention group were associated with reduced physical activity of 144 MET 
minutes per week, and a small increase in stress level and happiness score compared with the control group 
(Table 4). None of these differences (in physical activity, stress and happiness over 12 months) were statistically 
significant (Table 4). (Insert Table 4 here) 
 
3.3. Economic evaluation aggregating household member and patient 
QALYs and costs 
The incremental cost-effectiveness ratio disregarding spillover effects was GBP 10,271 (EUR 13,146) per 
QALY gained (this analysis is reported in section 2.1). For the 151 main household members, the self-
management intervention was estimated to generate mean incremental health care costs of GBP 13.37 (95% CI: 
-72.40 to 99.20) (EUR 17.11, 95% CI: -92.67 to 126.97) and mean incremental QALYs of -0.0006 (95% CI: -
0.025 to 0.023). These estimates were not statistically significant. By assuming that the effect on incremental 
QALYs applies to all 428 main household members in the trial (as 428 PSM-COPD patients reported the 
presence of a household member), the resulting ICER that was generated is GBP 10,991 (EUR 14,068) per 
QALY gained (scenario 1), and this ICER increased to GBP 12,913 (EUR 16,528) per QALY gained through 
the additional incorporation of household member health care costs (scenario 3). By assuming that change in 
incremental QALYs was only experienced by the responding 151 main household members, an ICER of GBP 
10,554 (EUR 13,509) per QALY gained was generated (scenario 2). An ICER of GBP 11,095 (EUR 14,201) per 
QALY gained was estimated for the analysis which assumed that the effect on incremental QALYs applies to 
491 household members (comprising of 428 main household members and 63 second household members) 
(scenario 4). These ICERs are below the cost-effectiveness thresholds that were proposed in the methods section 






The aim of this study was to examine whether a COPD behavioural intervention resulted in QALY changes in 
patients’ household members (‘household spillovers’), and to illustrate methods for including these spillovers in 
the economic evaluation of the intervention. Household members’ EQ-5D-5L scores were analysed over the 
course of 12 months, and it was found that there was negligible change resulting from the self-management 
intervention, with a non-significant 0.007 QALY decrease resulting from the intervention. The impact of 
including household member incremental QALYs on cost-effectiveness was small, because the magnitude of the 
household member incremental QALYs estimate was less than 10% of the magnitude of the patient incremental 
QALYs estimate. 
It is important to contextualise these results in terms of patient outcomes from the self-management intervention. 
Whilst the self-management intervention led to significant improvements in patients’ action planning, 
medication management and short-term physical activity, it did not produce a statistically significant effect on 
patients’ health related quality of life, smoking, or physical activity at 12 months (36), which may explain the 
absence of statistical significance in household member spillover outcomes. This pattern also emerged in the 
three previous trials which have measured family health spillovers, where the intervention did not have a 
significant impact on relevant patient outcomes in these contexts either (18-20). Absence of statistical 
significance in household member outcomes may also be explained by the relatively small sample of household 
members that were recruited to the study. Furthermore the household members of the intervention group 
patients were already exhibiting positive health behaviours at baseline. For instance, only 7% of household 
members in the intervention group reported being smokers, and 43% reported participating in high levels of 
physical activity. This may explain a potential lack of scope for the intervention in improving the health and 
health behaviours of household members. Another issue is that even when patient health status improves at a 
statistically significant level over the course of a trial, health spillovers may not do so, as health spillovers are 
generally much smaller in magnitude to direct patient health changes (51). There is also the question of whether 
health measures are appropriate to capture spillover. While evidence suggests they perform adequately (5), the 
use of a care-related quality of life measure may offer greater sensitivity in detecting changes in domains of 
wellbeing influenced by the caring role (e.g. ‘feeling supported’, ‘relationships’, ‘fulfilment’). However, care-
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related quality life may not be considered relevant to economic evaluations with the underlying purpose of 
maximising health-related quality-adjusted life years (52). 
This study highlights a number of methodological challenges for economic evaluations including spillover 
effects. First, spillover data may be partial, because some patients do not have household/family members and 
because some of those that do, may not respond. Second, health resource use data from household members may 
be considered relevant under a healthcare or a societal perspective. However it is also very rarely considered in 
economic evaluation, but may (as in this case) be a more important influence on the ICER than household 
members’ health outcomes, Third, ICER thresholds need to reflect the fact that spillovers are displaced (as well 
as patient QALYs) when interventions are funded from a fixed budget. The distributional implications from the 
routine incorporation of spillover effects in economic evaluation are also unclear and could be further explored. 
For example, although the elderly are more likely to receive informal care, they are also more likely to live 
alone. Similarly, although mental health conditions seem to be associated with relatively big spillovers (51), 
many people with mental health conditions are cut off from close family. 
This is the first CUA to consider health spillover generated from a behavioural health intervention; previous 
studies have only focused on drugs and clinical treatments for patients generating QALY effects in household 
members (23). The loss to follow-up of household members (n=24, sixteen percent) was not substantial and the 
characteristics of those lost to follow-up were similar to those retained. Therefore, loss to follow-up was 
unlikely to have resulted in substantial bias. A range of outcomes of household members were assessed in the 
between-groups analysis, including variables that might be associated with undetected future health spillovers. 
Furthermore, a novel approach was used for including household member QALYs in the economic evaluation, 
by adjusting the conventional NICE threshold, and adjusting for the 26% of PSM-COPD patients who lived 
alone through a 26% reduction of the estimate of incremental QALYs of household members. 
A limitation of this study was that the sample size of household members (n=153) was much smaller than the 
sample size of patients (n=577). This meant a lack of statistical power in the analysis of household member 
outcomes. It may have also resulted in the moderate imbalance that was observed between the characteristics of 
the family members at baseline.  The smaller sample size resulted from a combination of factors, with some 
patients living alone and recruitment of household members was via patients (and some patients or their 
household members decided not to participate). This may be an unavoidable problem in studies such as this one 
where household members or carers do not have face-to-face contact with the trial administrators (43).  
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In future RCTs, where data collection from household members is feasible and spillovers are likely to be 
generated from the intervention, we would recommend that all patients are asked whether they consent to 
enrolling their household members in data collection at baseline. Furthermore, there are ways in which 
researchers may be able to capture spillovers more fully than in this trial. For instance, future practice may wish 
to consider measuring household member outcomes over a longer time period in a trial, perhaps extending 
beyond the follow-up data collection for patients, as it may take time before household members’ health status is 
impacted by spillovers from the emotional and care burden generated by illness.  
Furthermore, in this study, we estimated patient incremental QALYs and household member incremental 
QALYs separately before aggregating the mean estimates. We considered the alternative option of carrying out 
an analysis of 151 patient-household member dyads to resemble the approach taken in other studies (19, 20). 
These were the dyads where both the patient and their related household member completed baseline 
questionnaires. However, such an analysis would have involved dropping 73% of patients (n=426) from the 
analysis as they did not have a participating household member. The advantage that a dyadic analysis has over 
the multiplier approach for including health spillovers is that it enables a probabilistic sensitivity analysis to be 
conducted to explore cost-effectiveness uncertainty. In future studies, we would recommend using a dyadic 
approach only where there is not a considerable number of patients who live alone or do not have an informal 
carer or family member participating in data collection, so that substantial amounts of patient data are not 
eliminated from the analysis.  
 
5. CONCLUSION  
This quantitative study found that a COPD self-management intervention aimed at improving the health of 
patients did not generate a large or statistically significant health spillover effects on household members over 
the course of 12 months. As a result, the impact of including health spillovers in the economic evaluation of the 
intervention was small. However, the study raises a number of methodological issues including the overall 
approaches available for including health spillover effects in an economic evaluation, the use of an appropriate 
factor to account for the non-existence of household spillover for patients who live alone, and the appropriate 
choice of threshold when including health spillovers in a cost-utility analysis. Furthermore the inclusion of 
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Table 1: Assumptions and justifications for the different scenarios used for including household spillover 
Scenario and assumption Justification 
Scenario 1. Only the patients in the trial who reported 
living with someone in the baseline questionnaire, 
generated a spillover. Number of household members 
per patient included: 1. Displaced spillover: 16%. 
Only these patients had the potential to generate a 
household spillover. This approach assumes that the 
household members who did not respond to the 
family impact survey incurred the same mean health 
spillover effect that was estimated for the main 
household members who did respond. 
Scenario 2: Only the patients who had a responding 
main household member, generated a spillover. 
Number of household members per patient included: 
1. Displaced spillover: 16%. 
This assumption was made due to the possibility that 
no health spillover was incurred among the non-
responding main household members. 
Scenario 3: Household member health care costs (GP 
and nurse) are included. Number of household 
members per patient included: 1. Displaced spillover: 
16%. 
It is plausible that family members whose health 
improves as a result of intervention spillover may 
require fewer health care visits 
Scenario 4: Both main household members as well as 
second household members are impacted by health 
spillover. Number of household members per patient 
included: 2. Displaced spillover: 32%. 
A proportion of responding patients recorded that 
their household included 3 (or more) adult 
individuals in total. This approach assumes that the 
household members who did not respond or were not 
included in the analysis of health spillover incurred 
the same mean health spillover effect that was 






Table 2: Descriptive statistics for intervention and usual care samples in FIS (baseline data) 




Household member (n=153)                                                                                                                
Female (n, %) 
Age (years, mean (SD)) 
Relationship to patient (spouse, n (%))  
EQ-5D-5L, (mean (SD)) 
Happiness (mean (SD)) 
Perceived Stress Scale (mean (SD)) 
Household size (two-person, n (%)) 
 
Patient (n=151) 
Female (n, %) 
Age (years, mean (SD)) 
SGRQ-C score (mean (SD)) 
EQ-5D-5L (mean (SD)) 
MRC Scale 1 n (%) 
                    2 n (%) 
 
Household member health behaviours 
Smokers (n (%)) 
Physical activity- Low (n (%)) 
                              Moderate (n (%))  




















































*SGRQ-C  (St Georges Respiratory Questionnaire for COPD) is a 0 to 100 disease-specific measure of COPD 
quality of life. Score of 100 indicates full COPD QoL                  
*MRC Scale is a measure of patients’ level of breathlessness (1 is an indicator of very mild breathlessness, 4 




Table 3. Comparison of change in EQ-5D-5L scores between intervention and control for all household 
members and spousal household members from baseline to 12 months 
 Mean EQ-5D-5L change   (sd) Between-groups analysis      (95% CI) 




Unadjusted n=114 Adjusted*   
n=114 
All household 












(-0.05 to 0.04) 
p=0.75 
Household members 








(-0.05 to 0.04) 
p=0.75 
-0.005 
(-0.05 to 0.04) 
p=0.82 
* Unadjusted analysis assesses the intervention effect on follow-up EQ-5D-5L, adjusted for baseline EQ-5D-5L. 
Adjusted analysis additionally adjusts for age and gender. 
 
Table 4. Comparison of change in physical activity, stress (PSS) and happiness between intervention and 
control for household members 
 Mean change (sd)        Between-groups analysis (95% CI) 
 Control   
n=44 
Intervention    
n=38 








50.7 (1632.2) -118.1  
(-824.3 to 588.1) 
p=0.74 
-144.4 













(-0.16 to 1.62) 
p=0.11 
0.69 




Happiness  (0 to 







(-0.23 to 0.67) 
p=0.34 
0.22  
(-0.23 to 0.67) 
p=0.34 
* Unadjusted analysis assesses the intervention effect on follow-up outcome, adjusted for baseline outcome. 
Adjusted analysis additionally adjusts for age and gender. 
 
